
Founded in 1983, the Charcot-Marie-Tooth Association is a non-profit dedicated to finding a cure for CMT and improving the quality of life for those affected by this rare neurological disorder. Occam placed Suzanne “Sue” Bruhn, a biotech industry veteran, as the organization’s Chief Executive Officer in November 2023.
Sue brings over a decade of biotech CEO experience to CMTA and a strong commitment to rare disease drug development and patient advocacy dating back to her tenure at Shire. Suzanne has a Ph.D. in Chemistry from MIT and completed her post-doctoral work at Harvard Medical School. She currently sits on the boards of Pliant Therapeutics, Travere Therapeutics, Vigil Neuroscience, and MindMed.
Occam’s work with CMTA is part of the firm's executive search practice for life science-focused foundations and non-profit organizations. Having successfully partnered with esteemed non-profits such as Gavi, the Vaccine Alliance, and theBill & Melinda Gates Foundation in the past, we are gratified by the opportunity to continue to apply our efforts toward philanthropic endeavors.
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.